Urotensin II in the development and progression of chronic kidney disease following ⅚ nephrectomy in the rat.

ABSTRACT:

New findings

What is the central question of this study? Urotensin II is upregulated in patients in the later stages of chronic kidney disease (CKD), particularly in individuals requiring dialysis. Could treatment with a urotensin II receptor antagonist slow progression of renal disease? What is the main finding and its importance? In the rat, expression of urotensin II and its receptor increased, extending into cortical structures as CKD progressed towards end-stage renal failure. Subchronic treatment with a urotensin receptor antagonist slowed but did not prevent progression of CKD. This suggests that urotensin II contributes to the decline in renal function in CKD.

Abstract

Elevated serum and urine urotensin II (UII) concentrations have been reported in patients with end-

SUBMITTER: Eyre HJ 

PROVIDER: S-EPMC6492238 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature